These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10633465)

  • 1. Calcium-sensing receptor and calcimimetic agents.
    Coburn JW; Elangovan L; Goodman WG; Frazaõ JM
    Kidney Int Suppl; 1999 Dec; 73():S52-8. PubMed ID: 10633465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The calcimimetic agents: perspectives for treatment.
    Frazão JM; Martins P; Coburn JW
    Kidney Int Suppl; 2002 May; (80):149-54. PubMed ID: 11982829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcimimetic agents: review and perspectives.
    Ureña P; Frazão JM
    Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
    Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
    J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcimimetic agents and the calcium-sensing receptor.
    Coburn JW; Maung HM
    Curr Opin Nephrol Hypertens; 2000 Mar; 9(2):123-32. PubMed ID: 10757216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcimimetics with potent and selective activity on the parathyroid calcium receptor.
    Nemeth EF; Steffey ME; Hammerland LG; Hung BC; Van Wagenen BC; DelMar EG; Balandrin MF
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):4040-5. PubMed ID: 9520489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of uremic bone disease using calcimimetic compounds.
    Olgaard K; Lewin E
    Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The extracellular calcium-sensing receptor: its role in health and disease.
    Brown EM; Pollak M; Hebert SC
    Annu Rev Med; 1998; 49():15-29. PubMed ID: 9509247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review.
    Ureña P
    Artif Organs; 2003 Sep; 27(9):759-64. PubMed ID: 12940896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcimimetics--a new treatment for hyperparathyroidism?].
    Piecha G; Chudek J; Wiecek A
    Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcimimetic and calcilytic drugs: just for parathyroid cells?
    Nemeth EF
    Cell Calcium; 2004 Mar; 35(3):283-9. PubMed ID: 15200152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcimimetics and hyperparathyroidism.
    Krebs LJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation and action of the calcium-sensing receptor.
    Drüeke TB
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V20-26. PubMed ID: 15284356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
    Antonsen JE; Sherrard DJ; Andress DL
    Kidney Int; 1998 Jan; 53(1):223-7. PubMed ID: 9453023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biology and clinical importance of the Ca(2+)-sensing receptor.
    De Luca F; Baron J
    Curr Opin Pediatr; 1998 Aug; 10(4):435-40. PubMed ID: 9757371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating mutations of the Ca2+-sensing receptor.
    Mancilla EE; De Luca F; Baron J
    Mol Genet Metab; 1998 Jul; 64(3):198-204. PubMed ID: 9719629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.